Coronary Artery Disease Pipeline Landscape Analysis, Clinical Trials: 30+ Companies and 30+ Pipeline Drugs

DelveInsight's, "Coronary Artery Disease Pipeline Insight, 2022" report provides comprehensive insights about 30+ Coronary Artery Disease companies and 30+ pipeline drugs in Coronary Artery Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. Coronary Artery Disease pipeline report also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

In the Coronary Artery Disease Pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Coronary Artery Disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Key takeaways from the Coronary Artery Disease Pipeline Report
• DelveInsight's Coronary Artery Disease Pipeline analysis depicts a robust space with 30+ active players working to develop 30+ pipeline treatment therapies.
• The leading Coronary Artery Disease Companies are working such as Idorsia Pharmaceuticals, AstraZeneca, Sinotau Pharmaceuticals, XyloCor Therapeutics, AdvanceCor, Sinotau Pharmaceuticals, GE Healthcare, Honya Medical Inc, Novartis Pharmaceuticals, and others
• Promising Coronary Artery Disease Pipeline therapies such as Vericiguat (BAY1021189), Isosorbide mononitrate (ISMN), Nitroglycerin, Prasugrel Loading Dose, clopidogrel, Rivaroxaban, mipomersen sodium, Moxifloxacin, MEDI6012, and others.
• The Coronary Artery Disease companies and academics are working to assess challenges and seek opportunities that could influence Coronary Artery Disease R&D. The therapies under development are focused on novel approaches to treat/improve Coronary Artery Disease.
Recent Developmental Activities in the Coronary Artery Disease Pipeline Report
• Selatogrel, is a small molecule being developed by Idorsia Pharmaceuticals. It acts as a P2Y12 receptor antagonist. Currently, the drug is being studied in Phase II stage of Clinical trial evaluation for the treatment of Coronary artery disease.
• Atuliflapon (formerly AZD 5718) is an orally available, small molecule, 5-lipoxygenase activating protein inhibitor, being developed by AstraZeneca. Currently, the drug is being studied in Phase II stage of clinical trial evaluation for the treatment of Coronary artery disease.
• XTR003 is a PET imaging radiopharmaceutical agent used to trace myocardial fatty acid metabolism. XTR003 is a modified fatty acid that enters the myocytes and passes through mitochondrial membrane by the same process as the natural existing fatty acids and then undergoes partial β-oxidation before being trapped in the mitochondria. In preclinical study XTR003 showed high myocardial uptake and retention. Currently, the drug is in Phase I stage of Clinical trial evaluation for the treatment of Coronary Artery Disease.

Request a sample and discover the recent advances in Coronary Artery Disease Clinical Trials @ https://www.delveinsight.com/sample-request/coronary-artery-disease-cad-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Coronary Artery Disease Overview

Coronary artery disease (CAD) is the most common type of heart disease in the United States. It is sometimes called coronary heart disease or ischemic heart disease. Coronary Artery Disease is caused by plaque buildup in the walls of the arteries that supply blood to the heart (called coronary arteries) and other parts of the body.Plaque is made up of deposits of cholesterol and other substances in the artery. Plaque buildup causes the inside of the arteries to narrow over time, which can partially or totally block the blood flow. This process is called atherosclerosis. Angina, or chest pain and discomfort, is the most common symptom of CAD. Angina can happen when too much plaque builds up inside arteries, causing them to narrow. Narrowed arteries can cause chest pain because they can block blood flow to the heart muscle and the rest of the body. Overweight, physical inactivity, unhealthy eating, and smoking tobacco are risk factors for CAD. Coronary Artery Disease is one of the most common chronic conditions: Nearly 10% of people between the ages of 40 and 80 are affected by it - men more often than women. Coronary Artery Disease is a chronic disease. Someone may first notice that they have it after experiencing angina symptoms, but Coronary Artery Disease can also cause a heart attack without any previous symptoms. Sometimes a heart attack might even go unnoticed. This is known as a silent heart attack. People who have nerve damage due to diabetes, for example, might not feel the typical symptoms of a heart attack. CAD can also lead to other health problems, most commonly heart attacks, heart rhythm problems like atrial fibrillation, and heart failure (cardiac insufficiency).Some people who have Coronary Artery Disease develop depression too. This is more likely following a heart attack. The main way to diagnose CAD is with an electrocardiogram (ECG). It is also possible to do an ultrasound scan of the heart (echocardiography) or use another imaging technique to examine the heart. The person's age, other medical conditions, and the type of symptoms will determine what additional testing might be needed. The main goals of treatment for Coronary Artery Disease are to relieve symptoms and prevent complications. Medication can reduce the symptoms and restrictions in everyday life caused by stable angina. Beta blockers, calcium channel blockers and nitrates are used for this purpose.

Coronary Artery Disease Emerging Drugs
• Selatogrel: Idorsia Pharmaceuticals
• Atuliflapon: AstraZeneca
• XTR 003: Sinotau Pharmaceuticals
Coronary Artery Disease Pipeline Therapeutic Analysis
There are approx. 30+ key Coronary Artery Disease companies which are developing the therapies for Coronary Artery Disease. The companies which have their Coronary Artery Disease drug candidates in the most advanced stage, i.e. Phase II include, Idorsia Pharmaceuticals.
DelveInsight's Coronary Artery Disease Pipeline report covers around 30+ Coronary Artery Disease products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Learn more about the emerging Coronary Artery Disease Treatment Landscape @ https://www.delveinsight.com/sample-request/coronary-artery-disease-cad-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Coronary Artery Disease Pipeline Report
• Coverage- Global
• Coronary Artery Disease Therapeutic Assessment by Product Type
• Coronary Artery Disease Assessment by Stage and Product Type
• Coronary Artery Disease Assessment by Route of Administration
• Coronary Artery Disease Assessment by Stage and Route of Administration
• Coronary Artery Disease Assessment by Molecule Type
• Coronary Artery Disease Assessment by Stage and Molecule Type
• Coronary Artery Disease Companies- Idorsia Pharmaceuticals, AstraZeneca, Sinotau Pharmaceuticals, XyloCor Therapeutics, AdvanceCor, Sinotau Pharmaceuticals, GE Healthcare, Honya Medical Inc, Novartis Pharmaceuticals, and others.
• Coronary Artery Disease Pipeline therapies- Vericiguat (BAY1021189), Isosorbide mononitrate (ISMN), Nitroglycerin, Prasugrel Loading Dose, clopidogrel, Rivaroxaban, mipomersen sodium, Moxifloxacin, MEDI6012, and others.

Table of Content
1. Introduction
2. Executive Summary
3. Coronary Artery Disease: Overview
4. Coronary Artery Disease Pipeline Therapeutics
5. Coronary Artery Disease Therapeutic Assessment
6. Coronary Artery Disease- DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Drug Name: Company Name
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Selatogrel: Idorsia Pharmaceuticals
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. XTR 003: Sinotau Pharmaceuticals
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name: Company Name
18. Drug profiles in the detailed report…..
19. Inactive Coronary Artery Disease Products
20. Coronary Artery Disease Key Companies
21. Coronary Artery Disease Key Products
22. Coronary Artery Disease- Unmet Needs
23. Coronary Artery Disease- Market Drivers and Barriers
24. Coronary Artery Disease- Future Perspectives and Conclusion
25. Coronary Artery Disease Analyst Views
26. Coronary Artery Disease Key Companies
27. Appendix

Key Questions
Current Treatment Scenario and Emerging Coronary Artery Disease Therapies:
• How many Coronary Artery Disease companies are developing Coronary Artery Disease drugs?
• How many Coronary Artery Disease drugs are developed by each company?
• How many emerging Coronary Artery Disease drugs are in mid-stage, and late-stage of development for the treatment of Coronary Artery Disease?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Coronary Artery Disease therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing Coronary Artery Disease therapies?
• What are the clinical studies going on for Coronary Artery Disease and their status?
• What are the key designations that have been granted to the emerging Coronary Artery Disease drugs?

Got Queries? Get in touch with our Business Development Executive, Coronary Artery Disease Pipeline Drugs @ https://www.delveinsight.com/report-store/coronary-artery-disease-cad-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

This release was published on openPR.